TY - JOUR
T1 - Cost and cost-effectiveness of treatments for rheumatic heart disease in low-and middle-income countries
T2 - A systematic review protocol
AU - Thangamma Ag, Mona Ag
AU - Vidyadharan, Bhavya
AU - Daniel, Roshan P.
AU - Sirur, Andria
AU - Kumar, Praveen
AU - Thunga, Girish G.
AU - Gopal Poojari, Pooja
AU - Rashid, Muhammed
AU - Mukherjee, Nirmalya
AU - Bhattacharya, Paramita
AU - John, Denny
N1 - Publisher Copyright:
© 2024 JBI.
PY - 2024/6/27
Y1 - 2024/6/27
N2 - Objective: This review will synthesize studies on costs, the impact of these costs, and the cost-effectiveness of treatments for rheumatic heart disease (RHD) in low-and middle-income countries. Introduction: RHD incurs high costs owing to its clinical complexity, surgical treatments, and prolonged hospital stays. Thus, the disease has a substantial economic impact on the health system, patients, and their families. No systematic review on economic evidence of treatments for RHD has been published to date. Inclusion criteria: This review will consider all cost and cost-effectiveness studies on RHD treatments for children and young adults (5─30 years) residing in low-and middle-income countries. Methods: The review will follow the JBI methodology for systematic reviews of economic evaluation evidence. The search strategy will locate published and unpublished studies in English. Systematic searches will be conducted in MEDLINE (PubMed), MEDLINE (Ovid), Embase (Ovid), Scopus, CINAHL (EBSCOhost), National Health Service Economic Evaluation Databases, Pediatric Economic Database Evaluation, and Cost-Effectiveness Analysis Registry. Two independent reviewers will screen titles and abstracts, followed by a full-Text review based on the inclusion criteria. Data will be extracted using a modified JBI data extraction form for economic evaluations. JBI's Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the results of cost and cost-effectiveness studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach will be used to assess the certainty of economic evidence for outcomes related to resource use. Review registration: PROSPERO CRD42023425850.
AB - Objective: This review will synthesize studies on costs, the impact of these costs, and the cost-effectiveness of treatments for rheumatic heart disease (RHD) in low-and middle-income countries. Introduction: RHD incurs high costs owing to its clinical complexity, surgical treatments, and prolonged hospital stays. Thus, the disease has a substantial economic impact on the health system, patients, and their families. No systematic review on economic evidence of treatments for RHD has been published to date. Inclusion criteria: This review will consider all cost and cost-effectiveness studies on RHD treatments for children and young adults (5─30 years) residing in low-and middle-income countries. Methods: The review will follow the JBI methodology for systematic reviews of economic evaluation evidence. The search strategy will locate published and unpublished studies in English. Systematic searches will be conducted in MEDLINE (PubMed), MEDLINE (Ovid), Embase (Ovid), Scopus, CINAHL (EBSCOhost), National Health Service Economic Evaluation Databases, Pediatric Economic Database Evaluation, and Cost-Effectiveness Analysis Registry. Two independent reviewers will screen titles and abstracts, followed by a full-Text review based on the inclusion criteria. Data will be extracted using a modified JBI data extraction form for economic evaluations. JBI's Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the results of cost and cost-effectiveness studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach will be used to assess the certainty of economic evidence for outcomes related to resource use. Review registration: PROSPERO CRD42023425850.
UR - http://www.scopus.com/inward/record.url?scp=85203653575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85203653575&partnerID=8YFLogxK
U2 - 10.11124/JBIES-23-00246
DO - 10.11124/JBIES-23-00246
M3 - Review article
C2 - 38932504
AN - SCOPUS:85203653575
SN - 2202-4433
VL - 22
SP - 1886
EP - 1897
JO - JBI evidence synthesis
JF - JBI evidence synthesis
IS - 9
ER -